DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Gastrografin (Diatrizoate Meglumine / Diatrizoate Sodium) - Summary

 
 



GASTROGRAFIN SUMMARY

Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is a palatable lemon-flavored water-soluble iodinated radiopaque contrast medium for oral or rectal administration only. Each mL contains 660 mg diatrizoate meglumine and 100 mg diatrizoate sodium; pH has been adjusted to 6.0 to 7.6 with sodium hydroxide. Each mL contains approximately 4.8 mg (0.21 mEq) sodium and 367 mg organically bound iodine.

Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous.

Gastrografin may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology.


See all Gastrografin indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Gastrografin (Diatrizoate Meglumine / Diatrizoate Sodium)

ESC: Diagnostic Testing in the Spotlight
Source: MedPage Today Cardiovascular [2015.08.27]
(MedPage Today) -- HS-troponin I and CT-based fractional flow reserve among top trials expected

New Coalition to Tackle Diagnostic Errors in Medicine
Source: Medscape Business of Medicine Headlines [2015.08.26]
The Coalition to Improve Diagnosis will shine a light on diagnostic errors in medicine and find ways to curb the problem, organizers say.
Medscape Medical News

Biocept launches its first liquid biopsy diagnostic test for colorectal cancer
Source: Colorectal Cancer News From Medical News Today [2015.08.25]
New test uses patient's blood sample to detect KRAS, predictive biomarker for solid tumor cancersBiocept, Inc.

New diagnostic tools for dehydration severity in children
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2015.08.21]
System may improve intake of cholera, diarrhea casesDehydration from diarrhea, either from viral infection or cholera, accounts for 10 percent of all child deaths worldwide.

Novel diagnostic tool for ethnically diverse non-small-cell lung cancer patients
Source: Lung Cancer News From Medical News Today [2015.08.17]
A new serum miRNA panel could lead to accurately and early diagnosing NSCLC in ethnically diverse patientsEarly-stage Non-small-cell Lung Cancer (NSCLC) is asymptomatic and difficult to detect...

more news >>

Published Studies Related to Gastrografin (Diatrizoate Meglumine / Diatrizoate Sodium)

Prospective randomized trial of iohexol 350 versus meglumine sodium diatrizoate as an oral contrast agent for abdominopelvic computed tomography. [2011.03]
CONCLUSION: Iohexol 350 is a satisfactory oral contrast agent for abdominopelvic CT. It opacifies the gastrointestinal tract as well as meglumine sodium diatrizoate does, and patients prefer the taste of iohexol to that of diatrizoate.

Clinical impacts of oral gastrografin follow-through in adhesive small bowel obstruction (SBO). [2010.08]
BACKGROUND: Many studies have shown that gastrografin can be used for diagnosis of adhesive small bowel obstruction (ASBO) and for assessing the need for surgical intervention. However, several studies have reported conflicting results. Therefore, the aim of this study is to assess the diagnostic and therapeutic effect of gastrografin in ASBO... CONCLUSIONS: Oral gastrografin helps in the management of ASBO. Oral gastrografin is safe and reduces the operative rate and time of resolution as well as hospital stay. Copyright 2010 Elsevier Inc. All rights reserved.

Water-soluble contrast medium (gastrografin) value in adhesive small intestine obstruction (ASIO): a prospective, randomized, controlled, clinical trial. [2008.10]
BACKGROUND: Patients with adhesive small intestine obstruction (ASIO) are difficult to evaluate and to manage and their treatment is still controversial. The diagnostic and therapeutic role of water-soluble contrast medium (Gastrografin) in ASIO is still debated. This study was designed to determine the therapeutic role of Gastrografin in patients with ASIO... CONCLUSIONS: Data showed that the use of Gastrografin in ASIO is safe and reduces the operative rate and the time to resolution of obstruction, as well as the hospital stay.

Water-Soluble Contrast Medium (Gastrografin) Value in Adhesive Small Intestine Obstruction (Asio): A Prospective, Randomized, Controlled, Clinical Trial. [2008.08.08]
BACKGROUND: Patients with adhesive small intestine obstruction (ASIO) are difficult to evaluate and to manage and their treatment is still controversial. The diagnostic and therapeutic role of water-soluble contrast medium (Gastrografin) in ASIO is still debated. This study was designed to determine the therapeutic role of Gastrografin in patients with ASIO... CONCLUSIONS: Data showed that the use of Gastrografin in ASIO is safe and reduces the operative rate and the time to resolution of obstruction, as well as the hospital stay.

Randomized controlled trial of Gastrografin in adhesive small bowel obstruction. [2005.08]
BACKGROUND: Several previous studies have shown that Gastrografin can be utilized to triage patients with adhesive small bowel obstruction (ASBO) to an operative or a non-operative course. Previous studies assessing the therapeutic effect of Gastrografin have been confounded by post-administration radiology alerting the physician to the treatment group of the patient. Therefore the aim of the present paper was to test the hypothesis that Gastrografin hastens the non-operative resolution of (ASBO)... CONCLUSIONS: Gastrografin accelerates resolution of ASBO by a specific therapeutic effect.

more studies >>

Clinical Trials Related to Gastrografin (Diatrizoate Meglumine / Diatrizoate Sodium)

Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants [Completed]
Gastrografin is a radiopaque contrast agent for the gastrointestinal tract (GIT) which can be applied orally or rectally. In neonatal intensive care, Gastrografin is used to detect otherwise radiologically invisible perforations or an insufficient GIT anastomosis after surgery. Furthermore it is used for the treatment of meconium ileus. Gastrografin has a strong osmotic effect and leads to water influx into the intestine lumen. Thereby the peristaltic movement is accelerated and the premature infant excretes stool during the hours following application. Therefore Gastrografin might be effective to mobilize meconium from small bowel and deep parts of the colon. The investigators hypothesized that enteral application of Gastrografin accelerates meconium evacuation in premature infants, and thereby enhances feeding tolerance in this population.

Study of the Effect of Water Soluble Oral Contrast (Gastrografin) on Postoperative Ileus After Colorectal Surgery [Completed]
The purpose of this trial is to determine whether the water-soluble contrast (gastrografin) is more effective in the treatment of postoperative ileus than the conventional one.

(Gastrografin Use in Small Bowel Obstruction Caused by Adherences) [Completed]
Adhesive small intestine obstruction (ASIO) is an important cause of hospital admission and a very common disease. Any improvement in this field will benefit many patients by reducing the operative rate. Patients with this disease are difficult to evaluate and to manage and their treatment is controversial. Emergency surgery is mandatory when strangulation is suspected or in the case of total obstruction. On the other hand, conservative non-operative treatment is indicated in the case of partial obstruction. The role of water-soluble contrast medium (Gastrografin®: GG) in ASIO is still debated with regard to the therapeutic value. The aim of our study was to determine the therapeutic role of Gastrografin in patients with small intestine obstruction without strangulation caused by adherences (ASIO).

Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO) [Completed]
Mini abstract : Altogether 100 patients with 117 episodes of ASBO were randomized into control and gastrografin groups. Eight episodes in eight patients were excluded. Gastrografin group showed a significant decrease of both the time between admission and operation and that of hospital stay .The need for surgery was reduced but statistically insignificant.

Gastrografin in Postoperative Ileus [Completed]
After abdominal surgery there is a period of unavoidable dysfunction of the gut. During this time patients are often unable to eat and drink, and do not pass any flatus or stool. Though this resolves within a few days for most, there are a significant number (around 30%) who go on to have a prolonged period of this dysfunction known clinically as postoperative ileus. It has been clearly shown that this group of patients have worse health outcomes and spend a longer time in hospital.

The aim of this study is to trial a drug - gastrografin - in the management of prolonged

postoperative ileus. Gastrografin is safe, economical, readily available, and has been used with great success in the similar condition of bowel obstruction. It is predicted that gastrografin will shorten the duration of a prolonged postoperative ileus, thus affording affected patients a better outcome from surgery.

more trials >>

Reports of Suspected Gastrografin (Diatrizoate Meglumine / Diatrizoate Sodium) Side Effects

Aspiration (3)Tachycardia (2)Blood Calcium Increased (2)Blood Sodium Increased (2)Bile Output (2)Hypotension (2)Blood Potassium Increased (2)Respiratory Distress (2)Diarrhoea (2)Pulseless Electrical Activity (2)more >>


Page last updated: 2015-08-27

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015